-
Poinsettia Pharmaceutical Montelukast Sodium Granules Approval for Marketing Approval
Time of Update: 2021-04-14
Figure 3: Enterprise competition of 2020E montelukast sodium granules in the retail market Source: Mi Nei. com, the competitive landscape of physical pharmacies in cities in China Montelukast sodium granules were included in the third batch of national procurement.
-
Jiahe Biologics STING agonist GB492 clinical trial application accepted
Time of Update: 2021-04-14
It is understood that a number of previous studies have shown that interferon gene stimulating factor (STING) agonists can be used in combination with immune checkpoint inhibitors (ICI) as a new immunostimulatory therapy that can enhance the efficacy of cancer immunotherapy.
-
The price of a batch of drugs is reduced by up to 85% (list attached)
Time of Update: 2021-04-14
In addition, the Gansu Provincial Drugs and Medical Consumables Centralized Procurement Network also issued the "Explanation on the Adjustment of Drug Prices Related to the Centralized Procurement of Drugs Organized by the State", which for the first time gave specific price reductions for unselected original drugs and generic drugs that passed the consistency evaluation.
-
There are more than 3 million Parkinson’s disease patients in China, and more than 90% of the respondents do not know that it can be treated by surgery
Time of Update: 2021-04-14
According to Professor Chen Haibo from the Department of Neurology of Beijing Hospital, in the past four years, the "Embrace the Tulip" campaign has held more than 100 professional doctor training sessions, covering more than 14,000 doctors; through more than 500 patient care actions, more than 100,000 patients have been rehabilitated.
-
State Administration of Traditional Chinese Medicine: Establishment of a treatment department in Chinese medicine hospitals above the second level
Time of Update: 2021-04-14
Efforts will be made to promote the establishment of a traditional Chinese medicine service system that integrates preventive health care, disease treatment and rehabilitation, and enhance service capabilities.
-
Efavirenz tablets, a subsidiary of Northeast Pharmaceuticals, obtained a drug registration certificate
Time of Update: 2021-04-14
Efavirenz tablets product indications are: This product is suitable for the treatment of adults, adolescents and children with HIV-1 infection in combination with other antiviral drugs.
In August 2003, efavirenz tablets were approved in China under the trade name Shidoning.
-
WuXi Biologics intends to establish a joint venture company for US$120 million to develop and produce ADCs and other drugs
Time of Update: 2021-04-14
After its establishment, WuXi XDC will be owned 60% and 40% by the company and Hequan Pharmaceutical, respectively.
According to the announcement, WuXi Biologics and Hequan Pharmaceuticals will strive to build WuXi XDC into an integrated and end-to-end contract development and production service (CDMO) company, specializing in the development and production of ADCs and other bioconjugate drugs.
-
Xinlitai SAL0104 Capsule was approved to carry out clinical trials for the prevention and treatment of thrombotic diseases
Time of Update: 2021-04-14
SAL0104 capsule is a coagulation factor XIa inhibitor, and its intended development indication is the prevention and treatment of thrombotic diseases.
Compared with similar products, coagulation factor XIa inhibitors can reduce the incidence of thrombosis and at the same time have the characteristics of low bleeding risk.
-
The state ordered!
Time of Update: 2021-04-14
Medical News, April 1st. On March 26th, the State Drug Administration issued the "Notice of the Comprehensive Department of the State Drug Administration on Carrying out the Inspection and Treatment
-
43 new drugs are coming: Hengrui, Qilu, Dongyang...
Time of Update: 2021-04-14
According to data from Meinenet, the sales of terminal protein kinase inhibitors in China's public medical institutions exceeded 20 billion yuan in 2019, a year-on-year increase of 59.
-
Biogen Alzheimer's monoclonal antibody aducanumab was criticized by the FDA committee
Time of Update: 2021-04-14
According to Bojian, the data of a group of patients who received a sufficiently high dose of drug treatment showed significant benefits in terms of cognition and function, including memory, orientation, and language, as well as benefits for activities of daily living.
-
The world's top ten pharmaceutical companies have reshuffled!
Time of Update: 2021-04-14
A few days ago, the Fierce Pharma website released a list of the top 20 global pharmaceutical companies by revenue in 2020. In the context of the global pandemic of the new crown epidemic, the ranki
-
Preliminary Pharmaceuticals obtains marketing approval for ganciclovir for injection from the Italian Food and Drug Administration
Time of Update: 2021-04-14
On April 1, Hainan Puli Pharmaceuticals issued an announcement that the company recently received a marketing authorization for ganciclovir for injection issued by the Italian Drug Administration (AIFA).
500mg ganciclovir for injection was applied by Roche Palo in June 1989 to be marketed in the United States under the trade name CYTOVENE®-IV.
-
The fifth innovative drug of Hausen Pharmaceuticals in the anti-tumor field in 2020 is about to be approved
Time of Update: 2021-04-14
The Insight database shows that only half a year after the original research was approved, Hansen Pharmaceuticals was the first to submit a listing application, which can be described as rapid.
-
The first imitation of Haisco's anti-ED drug is approved, and the blockbuster injection will start phase III clinical trials
Time of Update: 2021-04-14
for postoperative analgesia after abdominal laparoscopic surgery was recently approved by the CDE, and the subjects of the Phase III clinical trial can be started to be used in the group.
-
Official documents announced that the new "Regulations" will be formally implemented soon
Time of Update: 2021-04-14
Medical News, April 1st, Medical News, April 1st All cities involved On March 30, the National Medical Products Administration and the National Standardization Administration issued the "Opinions o
-
A batch of blockbuster first generic drugs are launched: CSPC, Hengrui, Haisco...
Time of Update: 2021-04-14
Medical Network News, April 2nd, less than ten days, a number of first imitation blockbuster listing CSPC's first imitation approved On April 1, CSPC announced that the “Amphotericin B Cholesterol Sulfate Complex for Injection” developed by its subsidiary CSPC Ouyi Pharmaceutical Co.
-
Gilead poached Amgen R&D executives
Time of Update: 2021-04-14
Bill Lee, who has served more than 30 years and announced his retirement, and will be responsible for running the entire R&D business of Gilead from April 12.
-
69 medicines, which are under the key monitoring and focus of medical insurance (list attached)
Time of Update: 2021-04-14
For drugs included in the key monitoring list, if the monthly delivery amount exceeds 5 million yuan, the online price will be lowered from the following month, and the maximum sales price limit and the medical insurance payment standard will be adjusted accordingly .
-
CSPC's Amphotericin B Cholesterol Sulfate Complex was officially approved
Time of Update: 2021-04-14
On March 31, the official website of NMPA showed that CSPC's 4 generic drugs "Amphotericin B Cholesterol Sulfate Complex for Injection" were officially approved for marketing (acceptance number: CYHS1900072).
Since then, Amphotericin B liposomes and Cholesterol Sodium Sulfate Complex for Injection (ABCD) have been listed on the international market.
